Optimizing Cell Line And Process Development Workflows For A Streamlined Path To FIH

In a recent webinar, KBI Biopharma process development experts Leslie Wolfe, Ph.D., and Shaunak Uplekar, Ph.D., discussed advanced cell line development (CLD) and transposase technology, exploring how each contributes to a streamlined path to toxicology studies as well as speed to first-in-human (FIH) studies. Following the webinar, the pair fielded questions submitted by participants, most of them seeking some behind-the-scenes insights into how KBI Biopharma accomplishes customer goals while providing a CDMO experience unlike any other in terms of speed, communication, and quality.